Unique Combination
Comprehensive Genomic Profiling (CGP) in Tumor and Liquid Biopsy with High‑Sensitivity ctDNA‑MRD Monitoring
- 01 - Unique Combination
- Uniquely Combining Genomic Profiling & ctDNA-MRD Monitoring
- 02 - Affordable Solution
- Tailored to Each Patient’s Clinical Condition
- Tumor-informed Methodology
- Tumor-naïve Methodology
- 03 - Efficient Solution
- Clinical Application for Early-Stage and Advanced-Stage Cancers
- Clinically Validated Performance of ctDNA-MRD Monitoring
- 04 - Cancer Types & Technical Specification
01
Unique Combination
K-TRACKTM bridges critical gaps in precision oncology by integrating comprehensive genomic profiling (CGP) with ctDNA-MRD detection on a single platform.
Our dual tissue-liquid biopsy profiling approach maximizes actionable mutation coverage, guiding targeted therapies and immunotherapies with superior accuracy. ctDNA-MRD monitoring delivers real-time treatment efficacy insights for timely adjustments and better outcomes.
ctDNA utility
In addition to minimal residual disease (MRD) detection, our unique assay simultaneously tracks both personalized tumor‑derived mutations and tumor‑agnostic mutations through liquid biopsy profiling using 3 large gene panels (113–149 genes). This enables comprehensive assessment of disease progression and early identification of emerging actionable or resistance mutations for improved clinical decision‑making.
Correlation of dynamic ctDNA and tumor progression
02
Affordable Solution
K-TRACKTM streamlines precision oncology through a unified workflow that optimizes costs and preserves critical tissue. We empower proactive management at every step, from therapy selection to surveillance.
Genomic Profiling
- Actionable and resistance mutations (detected in both tumor tissue and liquid biopsy)
- MSI Status
- Germline mutations (pharmacogenomics – DPYD and hereditary cancer risk assessment)
ctDNA-MRD Monitoring - No‑cost baseline ctDNA‑MRD assessment
- Affordable follow‑up ctDNA‑MRD tests
03
ctDNA assay Clinical Validation
K-TRACKTM assay provides longitudinal ctDNA monitoring that showed clinical utility in predicting disease-free survival and early relapse detection in cancer patients. 1,2,3,4,5
1. Front Oncol vol. 12 1069296. 12 Dec. 2022 | 2. Mol Oncol vol. 17,4 (2023): 598–610 | 3. CO Glob Oncol vol.9, Supp_1 (2023): 110– 110 | 4. Annals of Oncology 34 (2023): S1624 | 5. APBCS 2024 | 6. ESMO Real World Data and Digital Oncology 6 (2024): 100076
Performance Data
Evidence of Treatment Effectiveness & Early Recurrence
04
Cancer Types, Technical Specs & Turn-around Time
Cancer Types & Benefits from Test Results
| Panel | Cancer Type | Somatic Mutations (Actionable/Resistance) | ctDNA-MRD Monitoring | MSI Status | Germline Mutations | |
|---|---|---|---|---|---|---|
| Hereditary Cancer Risk | Pharmaco genomics | |||||
| Thoracic Cancers | Lung Cancer | |||||
| Mediastinal Cancer | ||||||
| Mesothelioma Cancer | ||||||
| Digestive Cancers | Ampulla of Vater | |||||
| Bladder Cancer | ||||||
| Cholangiocarcinoma | ||||||
| Colorectal Cancer | ||||||
| Esophageal Cancer | ||||||
| Gallbladder Cancer | ||||||
| Gastric Cancer | ||||||
| GIST | ||||||
| Liver Cancer | ||||||
| Pancreatic Cancer | ||||||
| Breast & Gynecological Cancers | Breast Cancer | |||||
| Cervical Cancer | ||||||
| Endometrial Cancer | ||||||
| Fallopian Tube Cancer | ||||||
| Ovarian Cancer | ||||||
| Uterine Cancer | ||||||
| Other | Prostate Cancer | |||||
Applicable to all cancer stages
Applicable to metastatic stage
| Turn-around Time (working days) | K-TRACK | K-TRACK BO |
|---|---|---|
| Actionable/ Resistance mutations | 05 days (1) | 8 days (3) |
| MSI Status | 05 days (1) | 8 days (3) |
| Germline mutations | 08 days (2) | 8 days (3) |
| ctDNA-MRD baseline | 08 days (2) | 8 days (3) |
| ctDNA-MRD follow-up | 08 days (3) | 8 days (3) |
(1) After receiving FFPE sample; (2) After receiving both FFPE and blood sample; (3) After receiving blood sample
(*) Turn-around time (TAT) begins once the sample arrives at a Gene Solutions lab and passes quality checks.Consequently, TAT may vary by country. Please contact our Gene Solutions representative in your country for the most accurate information.
